<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00722839</url>
  </required_header>
  <id_info>
    <org_study_id>City of Hope 03121</org_study_id>
    <secondary_id>R01CA077544</secondary_id>
    <secondary_id>P30CA033572</secondary_id>
    <secondary_id>CHNMC-03121</secondary_id>
    <secondary_id>CDR0000599724</secondary_id>
    <secondary_id>NCI-2010-01227</secondary_id>
    <nct_id>NCT00722839</nct_id>
  </id_info>
  <brief_title>Vaccine Therapy in Preventing Cytomegalovirus in Healthy Participants</brief_title>
  <official_title>A Phase I Dose Escalation Study of Peptide Vaccines With Activity Against Human Cytomegalovirus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>City of Hope Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>City of Hope Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines made from peptides may help the body build an immune response to kill&#xD;
      cytomegalovirus.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in&#xD;
      preventing cytomegalovirus in healthy participants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To establish whether 3 vaccine dose levels of PADRE-CMV and tetanus-CMV fusion peptide&#xD;
           vaccines are safe and well tolerated in healthy cytomegalovirus (CMV)-seropositive or&#xD;
           -seronegative participants.&#xD;
&#xD;
        -  To establish safe dose levels for the PADRE-CMV and tetanus-CMV fusion peptide vaccines&#xD;
           in combination with PF 03512676 DNA in these participants.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To provide preliminary evidence of enhanced cellular immunity to CMV at levels of T&#xD;
           cells that would support potential feasibility if such cells were to be transferred from&#xD;
           the donor to recipients of hematopoietic stem cell transplantation (HSCT) in amounts&#xD;
           consistent with protection against disease.&#xD;
&#xD;
        -  To determine whether a reduced dose of peptide vaccine can be immunogenic in combination&#xD;
           with PF 03512676 DNA.&#xD;
&#xD;
        -  To confer CMV-specific cytotoxic T-lymphocyte (CTL) function to CMV-negative&#xD;
           participants.&#xD;
&#xD;
        -  To determine the duration of immune enhancement of CMV-specific CTL function up to 12&#xD;
           months following immunization of healthy participants.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of PADRE-CMV and tetanus-CMV fusion peptide&#xD;
      vaccines. Participants are stratified according to cytomegalovirus (CMV) serum status&#xD;
      (positive vs negative). Participants are assigned to 1 of 2 groups.&#xD;
&#xD;
        -  Group A: Participants receive either PADRE-CMV fusion peptide vaccine or tetanus-CMV&#xD;
           fusion peptide vaccine subcutaneously (SC) on days 1, 21, 42, and 63 in the absence of&#xD;
           unacceptable toxicity.&#xD;
&#xD;
        -  Group B: Participants receive either PADRE-CMV fusion peptide vaccine in CpG 7909&#xD;
           adjuvant SC or tetanus-CMV fusion peptide vaccine in CpG 7909 adjuvant SC on days 1, 21,&#xD;
           42, and 63 in the absence of unacceptable toxicity.&#xD;
&#xD;
      Participants are contacted by telephone every 3-7 days after immunization. Participants also&#xD;
      complete a notebook on any health-related event for 14 days after each immunization.&#xD;
&#xD;
      Participants undergo blood sample collection at baseline and periodically during study for&#xD;
      immunologic laboratory studies, including flow cytometry, by HLA-A2-CMV-tetramer,&#xD;
      CMV-specific intracellular cytokine, CMV-specific CD107 degranulation, lymphoproliferation,&#xD;
      and chromium release assays.&#xD;
&#xD;
      After completion of study therapy, participants are followed for up to 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Successful completion of a series of 4 injections (at weeks 0, 3, 6, and 9) without dose-limiting toxicity</measure>
    <time_frame>3 weeks after the final vaccine dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose of each vaccine with or without adjuvant CpG 7909</measure>
    <time_frame>1 year after the final vaccine dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of CMV-positive and CMV-specific CD8+ T cells/L</measure>
    <time_frame>1 year after final vaccine dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Nonneoplastic Condition</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive either PADRE-CMV fusion peptide vaccine or tetanus-CMV fusion peptide vaccine subcutaneously (SC) on days 1, 21, 42, and 63 in the absence of unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive either PADRE-CMV fusion peptide vaccine in CpG 7909 adjuvant SC or tetanus-CMV fusion peptide vaccine in CpG 7909 adjuvant SC on days 1, 21, 42, and 63 in the absence of unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PADRE-CMV fusion peptide vaccine</intervention_name>
    <description>Given subcutaneously</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>tetanus-CMV fusion peptide vaccine</intervention_name>
    <description>Given subcutaneously</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>agatolimod sodium</intervention_name>
    <description>Given subcutaneously</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Cytomegalovirus (CMV) seropositivity or seronegativity&#xD;
&#xD;
          -  HLA A*0201 positive OR positive tetramer-binding using CMV peptide 495-503 with HLA A2&#xD;
             subtypes other than HLA A*0201&#xD;
&#xD;
          -  A2-CMV-Tet cells ≤ 10^8/L&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Platelet count within 1.5 times upper level of normal (ULN)&#xD;
&#xD;
          -  The following blood and chemistry studies must be normal:&#xD;
&#xD;
               -  Sodium&#xD;
&#xD;
               -  Potassium&#xD;
&#xD;
               -  Chloride&#xD;
&#xD;
               -  Carbon dioxide&#xD;
&#xD;
               -  Glucose&#xD;
&#xD;
               -  BUN&#xD;
&#xD;
               -  Creatinine&#xD;
&#xD;
               -  Uric acid&#xD;
&#xD;
               -  WBC&#xD;
&#xD;
               -  Hemoglobin&#xD;
&#xD;
               -  Hematocrit&#xD;
&#xD;
          -  The following studies must be ≤ ULN:&#xD;
&#xD;
               -  Albumin&#xD;
&#xD;
               -  Alkaline phosphatase&#xD;
&#xD;
               -  AST and ALT&#xD;
&#xD;
               -  Lactic dehydrogenase&#xD;
&#xD;
               -  Total bilirubin&#xD;
&#xD;
          -  Hepatitis B virus surface antigen negative&#xD;
&#xD;
          -  Hepatitis C virus seronegative&#xD;
&#xD;
          -  No diagnosis that is associated with immunodeficiency (e.g., HIV)&#xD;
&#xD;
          -  No active infection that requires treatment&#xD;
&#xD;
          -  No known cardiac disease including hypertension and/or high cholesterol&#xD;
&#xD;
          -  No serious abnormalities by EKG (in participants ≥ 50 years of age)&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile participants must use effective contraception during study and for 6 weeks&#xD;
             after the fourth and last dose of vaccine&#xD;
&#xD;
          -  No history of allergic reaction to tetanus toxoid&#xD;
&#xD;
          -  No history of any of the following:&#xD;
&#xD;
               -  Cancer other than basal cell carcinoma of the skin&#xD;
&#xD;
               -  Depression&#xD;
&#xD;
               -  Allergic diathesis, as defined by a history of asthma&#xD;
&#xD;
               -  Anaphylaxis&#xD;
&#xD;
               -  Generalized urticaria or daily use of antihistamines&#xD;
&#xD;
               -  Episodic (more than once in the past 3 months) inhalational medications including&#xD;
                  steroidal agents&#xD;
&#xD;
               -  Non-steroidal agents or cromolyn sodium&#xD;
&#xD;
               -  Frequent migraines, defined as 3 or more episodes in the past year&#xD;
&#xD;
          -  No prior or concurrent infectious condition&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  More than 6 months since prior participation in a CMV immunotherapy trial&#xD;
&#xD;
          -  More than 30 days since prior live vaccine&#xD;
&#xD;
          -  More than 2 weeks since prior inactivated vaccine&#xD;
&#xD;
          -  No concurrent daily medications for chronic or current illness, except for the&#xD;
             following:&#xD;
&#xD;
               -  Thyroid-replacement therapy&#xD;
&#xD;
               -  Estrogen-replacement therapy&#xD;
&#xD;
               -  Dietary vitamins and protein supplements&#xD;
&#xD;
               -  Any medication, as determined by the principal investigator, that is not known or&#xD;
                  likely to be immunosuppressive&#xD;
&#xD;
          -  No surgery in the past 6 months that required general anesthesia&#xD;
&#xD;
               -  Minor procedures (e.g., dental surgery or superficial diagnostics biopsies)&#xD;
                  allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John A. Zaia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>City of Hope Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010-3000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <study_first_submitted>July 25, 2008</study_first_submitted>
  <study_first_submitted_qc>July 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2008</study_first_posted>
  <last_update_submitted>June 21, 2012</last_update_submitted>
  <last_update_submitted_qc>June 21, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 25, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cytomegalovirus infection</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

